Cargando…
Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249656/ https://www.ncbi.nlm.nih.gov/pubmed/35795133 http://dx.doi.org/10.1002/iju5.12453 |
| _version_ | 1784739634034507776 |
|---|---|
| author | Tomisaki, Ikko |
| author_facet | Tomisaki, Ikko |
| author_sort | Tomisaki, Ikko |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9249656 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92496562022-07-05 Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate Tomisaki, Ikko IJU Case Rep Editorial Comment John Wiley and Sons Inc. 2022-04-10 /pmc/articles/PMC9249656/ /pubmed/35795133 http://dx.doi.org/10.1002/iju5.12453 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Editorial Comment Tomisaki, Ikko Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate |
| title | Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate |
| title_full | Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate |
| title_fullStr | Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate |
| title_full_unstemmed | Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate |
| title_short | Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate |
| title_sort | editorial comment to tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate |
| topic | Editorial Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249656/ https://www.ncbi.nlm.nih.gov/pubmed/35795133 http://dx.doi.org/10.1002/iju5.12453 |
| work_keys_str_mv | AT tomisakiikko editorialcommenttotrimodalitytherapywithi125brachytherapyexternalbeamradiationtherapyandshorttermhormonetherapyforhighriskprostatecancerafterholmiumlaserenucleationoftheprostate |